Kornimate/medical-research-clean huggingface dataset:
accelerated tooth movement with acceledent® and aligners - a pilot project

Conditions: Tooth Movement; Malocclusion

Summary: the acceledent® device has been introduced to the specialty of orthodontics in order to reduce treatment time. the theory behind acceledent® is that high frequency vibratory forces (30hz) delivered to the teeth will stimulate the bone remodeling that is necessary for tooth movement to occur more quickly. additionally, one claim of the acceledent® product is that it may reduce pain and discomfort during orthodontic treatment. this study will be a parallel group, triple-blind randomized clinical trial comparing two groups of subjects with 12 participants in each group. subjects will be randomized to receive one of two vibrational units, which will differ in frequency and/or amplitude of vibration. the subjects will be asked to change their aligners every week instead of every 2 weeks, which is common with invisalign.

this study will be a parallel group, triple-blind randomized clinical trial comparing two groups of subjects with 12 participants in each group. subjects will be randomized to receive one of two vibrational units, which will differ in frequency and/or amplitude of vibration. the subjects will be asked to change their aligners every week instead of every 2 weeks, which is common with invisalign.

Eligibility criteria:
inclusion criteria: 1. patients with malocclusions that require minor or no anterior-posterior or transverse correction in the posterior teeth, and are planned for \<= 25 aligners to complete treatment. 2. treatment must be dual arch in order for patients to qualify for this study. 3. patients must be 18 years or older exclusion criteria: 1. patients with systematic diseases or syndromes 2. patients with a history or current use of bisphosphonates 3. patients with current use of nonsteroidal anti-inflammatory drugs (nsaids)prostaglandin inhibitors. 4. patients with generalized moderate to severe periodontitis 5. patients with active oral hard tissue or soft tissue lesions 6. patients with chronic oral and maxillofacial conditions such as trigeminal neuralgia, temporomandibular disorder and orofacial pain.

Keywords: orthodontic orthodontic treatment accelerated orthodontics vibration
agility training in parkinson's disease

Conditions: Parkinson Disease

Summary: to determine the effects of an unusually highly intensity and individualized sensorimotor and visuomotor agility exercise program on non-demented pd patients' clinical symptoms, mobility, and postural stability.

design: intervention study setting: outpatient rehabilitation center participants: 55 parkinson's disease (pd) patients completed the trial and 42 serves as comparison healthy controls intervention: an initial screening established specific dysfunctions of pd patients with hoehn-yahr stage 2-3 who were then randomly assigned to standard care (n = 20) or standard care plus at-limit intensity, individualized agility program (15 sessions, 3 weeks, n = 35). main outcome measures: movement disorder society unified parkinson disease rating scale, motor experiences of daily living, a measure sensitive to changes in a broad spectrum of pd symptoms in group time, repeated measurements of variance analysis were compared to the picture parkinson's disease based on mds-updrs m-edl, beck depression score, pdq-39, eq5d vas, schwab \& england scale. the tug test and 12 static posturographic measurements are compared and compared to the healthy group as a standard. an at-limit and individualized sensorimotor and visuomotor agility exercise program vs. standard care, will improve non-demented, stage 2-3 pd patients' clinical symptoms, mobility, and postural stability by functionally meaningful margins.

Eligibility criteria:
inclusion criteria: * parkinson's disease * hoenh yahr scale of 2-3 * instability problem exclusion criteria: * severe heart problems * severe demeanor * alcoholism * drug problems

Keywords: sensorimotor training exergaming posture quality of life
low birth weight fetuses with caffeine use

Conditions: Low; Birthweight, Extremely (999 Grams or Less)

Summary: globally, it has been estimated that 15.5% of all infantsare born low birth weight, defined as birthweight less than 2,500 g .

low birth weight is not only associated with neonatal mortality and morbidity. but also with a higher risk of chronic diseases such as type 2 diabetes and cardiovascular diseases in adult life

Eligibility criteria:
inclusion criteria: * age group: 18-40 * pregnant females attending regular post-natal care visits exclusion criteria: * • female patients with other acute or chronic illness * cardiovascular disease * neoplasms * current diabetes mellitus, pregnancy induced diabetes * renal impairment (serum creatinine 120 mol/liter), and hypertension (blood pressure 140/85 mm hg).
heart healthy lenoir: return of results study

Conditions: Cardiovascular Disease

Summary: the investigators are conducting a two group intervention to study to the effect of individualized heart disease genomic risk results on motivation towards diet and physical activity behaviors to reduce heart disease risk. the intervention includes provided participants with genomic and lifestyle risk estimates. investigators will follow participants for 3 months to determine if motivation towards and engagement in diet and physical activity behaviors change.


Eligibility criteria:
inclusion criteria: * enrolled in heart healthy lenoir genomics * african-american (self-identified) * wants to be contacted for future studies exclusion criteria: * enrolled in an arm of the heart healthy lenoir lifestyle study with intense behavioral intervention (e.g. weight loss or weight maintenance programs)

Keywords: return of results genomics
fibricheck detection capabilities for atrial fibrillation

Conditions: Atrial Fibrillation

Summary: evaluation of accuracy of the fibricheck mobile application on various smartphone devices, compared to the reference diagnosis.


Eligibility criteria:
inclusion criteria: * at least 22 years old; * capable of independently performing fibricheck recordings (researcher-observed); * cardiology patients, hospitalized/in-clinic or consulting the cardiac outpatient clinic, with or without a diagnosis of atrial fibrillation. exclusion criteria: * individuals with cardiac pacemakers, implantable cardioverter-defibrillators, or other implanted electronic devices as these can influence the natural heart rhythm; * individuals enrolled in another clinical trial; * individuals with physical or medical characteristics that prevent them from successfully taking a measurement e.g. extreme callus (i.e., rough or thickened area of skin fingertip), tremor, cognitive impairment, parkinson's disease; * pregnant and/or nursing women.
real-world study on the efficacy of ibi-322 in combination with lenvatinib for the treatment of extensive stage small cell lung cancer

Conditions: Extensive-stage Small-cell Lung Cancer

Summary: this is a descriptive observational study, in which data are collected in an epidemiological fashion and prospective. this study does not intend to intervene the current medical practice of the recruited patients.


Eligibility criteria:
inclusion criteria: * patients must be ≥18 years. * provision of fully informed consent prior to any study specific procedures. * patients with extensive stage sclc diagnosed by pathology (as staged by the american veterans lung cancer association (valg)), who do not have an imaging response during first-line treatment with pd-(l)1 inhibitors, or who progress after imaging reactions on first-line therapy (the most recent regimen prior to enrollment must contain pd-(l)1 inhibitors). * according to the recist 1.1 standard, the patient must have at least one measurable lesion. exclusion criteria: * none
comparative effectiveness of psoriasis treatments on systemic inflammation

Conditions: Psoriasis; Inflammation

Summary: this is a prospective longitudinal observational pilot study of psoriasis patients on continuous standard-of-care systemic therapeutics to determine the level of change in established (plasma/serum) and investigative (cellular) biomarkers that are associated with increased risk of cvd events. the final endpoint of the proposed study will be a ranking of the examined biomarkers based upon an integrated assessment of biomarker behavior over time. secondary outcomes will assess changes in coronary artery calcification scoring, pet-mri, skin biopsies, and clinical improvement.


Eligibility criteria:
inclusion criteria: * subjects ages 18-65 years old * diagnosis of moderate-to-severe plaque psoriasis * plaque affects ≥ 10% of subject's body surface area (bsa) * subjects prescribed one of the following standard-of-care treatments for their psoriasis: ustekinumab, methotrexate, etanercept, adalimumab, narrow band uvb (311nm), excimer laser treatment (308nm), or acitretin * subjects willing to complete a washout period prior to visit 1 (only for subjects currently on a psoriasis treatment): * discontinue systemic therapies for at least 4 weeks * discontinue topical therapies for at least 2 weeks * discontinue phototherapies for at least 2 weeks exclusion criteria: * subjects who are currently on a psoriasis treatment and unwilling to go through the washout-period * subjects with a critical illness or who are immunocompromised * weight is 400lbs or greater * subjects who are currently pregnant or breastfeeding * subjects who have metal implants * subjects who have a pacemaker, stent, or artificial heart valve * history of clinically significant hematological, renal or liver disease * patients with known co-morbidities that raise biomarkers such as: * history of myocardial infarction (mi) * history of cerebrovascular accident (cva) * significant atherosclerosis (defined as the presence of any carotid plaque; or carotid intimal media thickness (cimt) \>75th percentile for age; or the presence of coronary artery calcium score\>100) * poorly controlled diabetes (elevated hba1c \> 8.5)

Keywords: psoriasis, comparative effects, inflammation
the angiotensin converting enzyme (ace) inhibitor switchback study

Conditions: Heart Failure

Summary: ace inhibitors have been studied extensively in the treatment of heart failure and have been shown to be beneficial in all its stages. studies with the use of angiotensin receptor blockers (arbs) in chronic heart failure have not shown equivalent results. many patients are on an arb for a variety of reasons. some of these may have had cough as a symptom of heart failure and not due to medication side effect. according to guidelines, angiotensin converting enzyme inhibitors (acei) are still first-line therapy in the treatment of heart failure. as acei have been extensively studied showing improvement in morbidity and mortality all patients should be on this treatment unless absolutely contraindicated.


Eligibility criteria:
inclusion criteria: * heart failure patients who have indications for acei but are currently on arbs with no absolute contraindications to acei * patients with an ejection fraction of \< or = 35% verified in the last 12 months by echo, angio, or nuc med who are nyha class i to iv and followed in a heart failure clinic for three months * on beta-blockers, unless contra-indicated * stable on current meds for 3 months (except dose of diuretics) * able to give informed consent exclusion criteria: * documented angioedema/anaphylaxis with prior acei use * documented worsening renal failure, hyperkalemia, cough and gastrointestinal symptoms that are definitely believed to be due to acei * potassium \>5.0 mmol/l

Keywords: ace inhibitors arbs
leflunomide for henoch-schonlein purpura

Conditions: Henoch-Schonlein Purpura

Summary: this study conducted a prospective, multicenter, one-arm clinical trial on the combination of leflunomide and steroid therapy for refractory skin henoch-schonlein purpura in children on the basis of ethical principles. a one-year follow-up was conducted to evaluate the changes in the main indicators (frequency of rash recurrence) and secondary indicators (proportion of kidney damage, proportion of joint involvement, t lymphocyte subpopulations, and inflammatory factors) before and after treatment, exploring the safety and effectiveness of leflunomide in the treatment of refractory skin type hsp in children, it is expected that leflunomide combined with conventional treatment can improve the remission rate of hsp children's skin purpura and reduce hsp recurrence. the research results are expected to bring new treatment methods and strategies for this group of patients.


Eligibility criteria:
inclusion criteria: 1. age ranges from 1 to 18 years old; 2. patients meet the hsp diagnostic criteria; 3. refractory skin type hsp: rashes are dense and large in area, often treated with antibiotics, antihistamines, calcium supplements, and glucocorticoids (2 mg/kg/d) for 5 days. the rash does not subside or fresh rash still appears, and frequently repeated more than 3 times during hospitalization. 4. parents or guardians agree to treatment and sign a written informed consent form. exclusion criteria: 1. individuals who are allergic to leflunomide; 2. concomitant severe underlying diseases (such as systemic malignancy, heart failure, liver and kidney failure, immune deficiency, severe infectious diseases, organ transplant surgery, or other current indications for emergency surgery); 3. patients with other digestive system diseases; 4. those who have previously used flumiphene in clinical trials; 5. excluding purpura caused by drugs, infectious factors, and other autoimmune diseases. 6. other situations where the researcher deems it inappropriate to participate in the study.

Keywords: leflunomide henoch-schonlein purpura children efficacy
safety and immunogenicity of 13-valent pneumococcal conjugate vaccine (13vpnc) in hiv-infected subjects 6 years of age or older who are naive to pneumococcal vaccine

Conditions: HIV Infections; Pneumococcal Infections

Summary: the study will evaluate the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate vaccine (13vpnc) in hiv-infected subjects 6 years of age or older who have not been previously immunized with a pneumococcal vaccine. all subjects will receive 3 doses of 13vpnc and 1 dose of 23-valent pneumococcal polysaccharide vaccine (23vps), with each dose given approximately 1 month apart.


Eligibility criteria:
inclusion criteria: * human immunodeficiency virus (hiv)-infected subjects aged 6 years or older * viral load \ = 200/ul within 6 months before study vaccination * receiving stable highly active antiretroviral therapy (haart) or not currently receiving any antiretroviral therapy * no previous vaccination with a pneumococcal vaccine * subject or parent/legal guardian able to complete an electronic diary exclusion criteria: * acquired immune deficiency syndrome (aids) at time of enrollment * current illicit substance and/or alcohol abuse * history of active chronic viral hepatitis * previous anaphylactic reaction to a vaccine or vaccine-related component * serious chronic disorders including metastatic malignancy and end-stage renal disease

Keywords: vaccine 13-valent pneumococcal conjugate vaccine 23-valent pneumococcal polysaccharide vaccine human immunodeficiency virus
the effects of multi-psycho-oncology care courses

Conditions: Cancer; Psychological; Oncology; Empathy

Summary: when the patient's mood has not yet reached a moderate to high severity level, psychological support is usually provided by the clinical nurses. however, the result of past research showed that the needs of patients and their caregivers were not satisfied with the psychological level. scholars pointed out that it may be related to factors such as excessive clinical workload or insufficient psychological support and care capacity. in addition, under the influence of covid-19 in the past two years, medical staff are facing more physical and mental pressure. oncology nurses have a heavy workload and are affected by the covid 19 epidemic, which reflects that nurses need psychological support. therefore, this study intends to reduce stress through remote physical and mental support activities, and use the internet to intervene in guided relaxation and meditation. considering the scheduling of clinical nurses, a remote and unstructured course content that does not require continuity will be selected, and then advanced to provide the empathetic care skills of oncology nurses.


Eligibility criteria:
intervention group * inclusion criteria: * over 20 years old (inclusive) * oncology nurses currently working in clinical practice * exclusion criteria: * those who are unwilling or unable to participate in this course training for a full one- year period. * those who have registered for the advanced oncology nursing course organized by the society in the current year. control group * inclusion criteria: * over 20 years old (inclusive) * oncology nurses currently working in clinical practice * those who have registered for the advanced oncology nursing course organized by the society in the current year * exclusion criteria: * those who have participated in multiple oncology psychological care courses, those who are unwilling or unable to participate in the training of distance psychological support courses for a full one-year period. * those who participate in the advanced course of oncology nursing are unwilling or unable to participate in the data evaluation of the complete bi-annual time point. * those who have participated in this research project.

Keywords: cancer oncology nurse psychological support empathy training course
valsartan versus amlodipine effect on left ventricular multidirectional deformation and adipocytokines level

Conditions: Hypertension

Summary: aim: to evaluate the effects of valsartan versus amlodipine on lv deformation in relation to plasma adiponectin and leptin levels in hypertensive individuals. methods: lv strain measured by 2 dimensional speckle tracking echocardiography, plasma levels of adiponectin and leptin was determined in 30 healthy individuals served as control group and in 200 hypertensive patients before and after treatment for three months with either valsartan 160 mg or amlodipine 10 mg.

patients and methods thirty control healthy individuals and 200 patients with uncomplicated, essential hypertension were enrolled and followed up for 3 months in a controlled randomized study. all subjects' health status was evaluated by a complete medical examination. all bp measurements were made with calibrated mercury manometers (korotkoff i and v). three separate measurements were taken at least 2 min apart and the average of these values was calculated. subjects' height and weight were recorded in the fasting state with the subjects wearing only light clothes and without shoes and bmi was calculated using the equation (bmi = weight (kg)/height (m)2). patients, of both sexes with mild to moderate essential hypertension (diastolic blood pressure \[dbp\] \>80 and ≤100 mmhg after a 2-week wash-out period, sbp systolic blood pressure\>120 and 160 mmhg). patients were randomly assigned into two groups using a computer-generated random number: group i treated with valsartan (160 mg/d, n = 100), group ii amlodipine (10 mg/d, n = 100). another 30 healthy subjects are enrolled as control group (group iii). subjects in group i and ii were asked to maintain their usual dietary and physical activity habits throughout the study. treatment tolerability was assessed at each follow-up visit.

Eligibility criteria:
inclusion criteria: * patients, of both sexes with mild to moderate essential hypertension (diastolic blood pressure \[dbp\] \>80 and ≤100 mmhg after a 2-week wash-out period, sbp systolic blood pressure\>120 and 160 mmhg). another 30 healthy subjects are enrolled as control group. exclusion criteria: * subjects with age \ 65 years and those with two and more antihypertensive medications, those with diabetes, liver or kidney diseases, angina, myocardial infarction or stroke within 6 months, congestive heart failure, neurologic or psychiatric illness, secondary hypertension, known hypersensitivity to the drugs used in the study. also those with conditions that may have caused metabolic alterations within the past year (pregnancy, abdominal surgery, weight gain or loss of more than 3 kg) are excluded.
oxygen therapy remote monitoring in copd patients.

Conditions: Chronic Obstructive Pulmonary Disease

Summary: background : long-term oxygen therapy is prescribed for patients with severe copd. the aim of oxygen therapy is to administer oxygen at a concentration level higher than that of ambient air, in order to treat or prevent the symptoms and manifestations of arterial hypoxemia; this therapy can be applied either in an acute situation or as a long-term treatment, in cases of stabilized severe chronic hypoxemia. currently, pneumologists do not have the possibility, between 2 consultations spaced several months apart, to measure the patient's compliance with the treatment (adherence to oxygen therapy) nor the respect of the prescribed dosage (o2 flow and duration). in addition to the patient's adherence to the treatment, the specialist does not have the possibility to assess the patient's physical activity (walking ...). this observational study is a e-health, prospective, multicenter study conducted in france under the control of pneumologists. the main objective of this study is to evaluate the adherence to oxygen therapy in real life, and its evolution, in copd patients justifying a long term oxygen therapy in stable state.

the observational study consists in collecting physiological data (cardiorespiratory and physical activity) and use of the oxygen therapy device in real life during the first months after the initiation of treatment. for this purpose, two connected medical devices will be provided to each patient during 2 periods of 2 weeks (weeks 6 to 8 then weeks 12 to 14 after the initiation of oxygen therapy). the devices are: 1/ a connected watch that continuously measures vital parameters (heart rate and blood oxygen saturation), and physical activity parameters (no. of steps, distance, duration of effort), and 2/ a teleox device that remotely monitors patients equipped with an oxygen source (it measures the oxygen flow rate requested by the patient, the duration of use of the oxygen source, and the breathing rate). study design: a cohort of 250 patients with copd newly initiated a long term oxygen therapy will be enrolled in the study and follow-up over 6 months. data will be collected by lung specialists and home health care provider teams at 2 months, 3.5 months and 6 months post-initiation of oxygen therapy.

Eligibility criteria:
inclusion criteria: * copd patients who require the initiation of a long term oxygen therapy. * patient agreeing to use a connected watch and a teleox for the remote monitoring of their parameters and physical activity. * non-smoker, ex-smoker, or patient agreeing to stop smoking. * life expectancy greater than 6 months. * signed informed consent form, * subject affiliated to a health insurance system, or is a beneficiary. exclusion criteria: * patient initiated on oxygen therapy prior to the inclusion visit. * patient with cognitive impairment. * simultaneous participation in a health intervention research, * vulnerable subjects.

Keywords: long term oxygen therapy compliance quality of life exacerbation